Biogen's (BIIB) Big Moves Signal Future Sale
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion
July 21, 2016 7:00 AM EDTSecond quarter 2016 GAAP diluted EPS rise 22%; Non-GAAP diluted EPS rise 23%
Company raises financial guidance for the year and authorizes $5 billion share repurchase program
George A. Scangos, Ph.D., to step down as CEO
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2016 financial results, including:
Total revenues of $2.9 billion, a 12% increase versus the same period in the prior year. Growth was driven by increases in worldwide revenues from the Companys multiple sclerosis (MS) and hemophilia... More